CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML
April 15th, 2019 by Michael E. Vinyard
CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML
CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML, Published online: 15 April 2019; doi:10.1038/s41589-019-0263-0
A CRISPR–Cas9 screening-based structure–activity relationship profiling method reveals that LSD1 inhibitors suppress acute myeloid leukemia by disruption of the interaction between LSD1 and GFI1B instead of the enzyme activity of LSD1.